The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
Open accessAbstract
Epilepsy is a common neurological disorder that affects over 70 million people worldwide. Despite the recent introduction of new antiseizure drugs (ASDs), about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Early identification of patients who will become refractory to ASDs could help direct such patients to appropriate non-pharmacological treatment, but the complexity in the temporal patterns of epilepsy could make such identification difficult. The target hypothesis and transporter hypothesis are the most cited theories trying to explain refractory epilepsy, but neither theory alone fully explains the neurobiological basis of pharmacoresistance. This review summarizes evidence for and against several major theories, including the pharmacokinetic hypothesis, neural network hypothesis, intrinsic severity hypothesis, gene variant hypothesis, target hypothesis, and transporter hypothesis. The discussion is mainly focused on the transporter hypothesis, where clinical and experimental data are discussed on multidrug transporter overexpression, substrate profiles of ASDs, mechanism of transporter upregulation, polymorphisms of transporters, and the use of transporter inhibitors. Finally, future perspectives are presented for the improvement of current hypotheses and the development of treatment strategies as guided by the current understanding of refractory epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G., Moshé, S. L., Perucca, E., Wiebe, S., & French, J. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02397.x · Cited by 4,877
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
Devinsky, O., & Pacia, S. (1993) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30132-4 · Cited by 1,175
Patterns of treatment response in newly diagnosed epilepsy
Brodie, M. J., Barry, S. J. E., Bamagous, G. A., Norrie, J. D., & Kwan, P. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563b19 · Cited by 931
Engel, J., Wiebe, S., French, J., Sperling, M., Williamson, P., Spencer, D., Gumnit, R., Zahn, C., Westbrook, E., & Enos, B. (2003) · Neurology · doi:10.1212/01.wnl.0000055086.35806.2d · Cited by 904
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
The consequences of refractory epilepsy and its treatment
Laxer, K. D., Trinka, E., Hirsch, L. J., Cendes, F., Langfitt, J., Delanty, N., Resnick, T., & Benbadis, S. R. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.05.031 · Cited by 679
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W., & Sisodiya, S. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021986 · Cited by 665
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma
Löscher, W., & Schmidt, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03024.x · Cited by 590
MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy
Tishler, D. M., Weinberg, K. I., Hinton, D. R., Barbaro, N., Annett, G. M., & Raffel, C. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb01657.x · Cited by 527
Predictors of pharmacoresistant epilepsy
Hitiris, N., Mohanraj, R., Norrie, J., Sills, G. J., & Brodie, M. J. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2007.06.003 · Cited by 527
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Palmeira, A., Sousa, E., H. Vasconcelos, M., & M. Pinto, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167392 · Cited by 484
Sisodiya, S. M., Lin, W. ‐., Harding, B. N., Squier, M. V., & Thom, M. (2002) · Brain · doi:10.1093/brain/awf002 · Cited by 479
Morris, G. L., Gloss, D., Buchhalter, J., Mack, K. J., Nickels, K., & Harden, C. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a393d1 · Cited by 450
Marson, A., Jacoby, A., Johnson, A., Kim, L., Gamble, C., & Chadwick, D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66694-9 · Cited by 438
Refractory Epilepsy: Clinical Overview
French, J. A. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00992.x · Cited by 430
Dombrowski, S. M., Desai, S. Y., Marroni, M., Cucullo, L., Goodrich, K., Bingaman, W., Mayberg, M. R., Bengez, L., & Janigro, D. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.12301.x · Cited by 426
Incidence of epilepsy: A systematic review and meta-analysis
Ngugi, A. K., Kariuki, S. M., Bottomley, C., Kleinschmidt, I., Sander, J. W., & Newton, C. R. (2011) · Neurology · doi:10.1212/wnl.0b013e31822cfc90 · Cited by 425
Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs
Löscher, W., & Potschka, H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.7 · Cited by 409
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123695.22623.32 · Cited by 407
Molecular and cellular mechanisms of pharmacoresistance in epilepsy
Remy, S., & Beck, H. (2006) · Brain · doi:10.1093/brain/awh682 · Cited by 406
Early development of intractable epilepsy in children: A prospective study
Berg, A. T., Shinnar, S., Levy, S. R., Testa, F. M., Smith–Rapaport, S., & Beckerman, B. (2001) · Neurology · doi:10.1212/wnl.56.11.1445 · Cited by 379
Nies, A. T., Jedlitschky, G., König, J., Herold-Mende, C., Steiner, H. H., Schmitt, H.-P., & Keppler, D. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.07.051 · Cited by 379
Tate, S. K., Depondt, C., Sisodiya, S. M., Cavalleri, G. L., Schorge, S., Soranzo, N., Thom, M., Sen, A., Shorvon, S. D., Sander, J. W., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407346102 · Cited by 345
Development of new antiepileptic drugs: challenges, incentives, and recent advances
Perucca, E., French, J., & Bialer, M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70215-6 · Cited by 339
Multidrug Resistance Proteins (MRPs, ABCCs): Importance for Pathophysiology and Drug Therapy
Keppler, D. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_8 · Cited by 318
Zhou, S.-F., Wang, L.-L., Di, Y., Xue, C., Duan, W., Li, C., & Li, Y. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785132870 · Cited by 318
Quantifying the response to antiepileptic drugs: Effect of past treatment history
Schiller, Y., & Najjar, Y. (2008) · Neurology · doi:10.1212/01.wnl.0000286959.22040.6e · Cited by 313
Several major antiepileptic drugs are substrates for human P-glycoprotein
Luna-Tortós, C., Fedrowitz, M., & Löscher, W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.032 · Cited by 310
Selective Alterations in GABAAReceptor Subtypes in Human Temporal Lobe Epilepsy
Loup, F., Wieser, H.-G., Yonekawa, Y., Aguzzi, A., & Fritschy, J.-M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-14-05401.2000 · Cited by 307
Leschziner, G. D., Andrew, T., Pirmohamed, M., & Johnson, M. R. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500413 · Cited by 300
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy
Kwan, P., & Brodie, M. J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.31904.x · Cited by 281
A novel mechanism underlying drug resistance in chronic epilepsy
Remy, S., Gabriel, S., Urban, B. W., Dietrich, D., Lehmann, T. N., Elger, C. E., Heinemann, U., & Beck, H. (2003) · Annals of Neurology · doi:10.1002/ana.10473 · Cited by 275
Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Agarwal, S., M.S. Hartz, A., F. Elmquist, W., & Bauer, B. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797440186 · Cited by 272
Self-citationBauer, B., Hartz, A. M. S., Pekcec, A., Toellner, K., Miller, D. S., & Potschka, H. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.041210 · Cited by 270
Self-citationTreatment of first tonic-clonic seizure does not improve the prognosis of epilepsy
Musicco, M., Beghi, E., Solari, A., Viani, F., & First Seizure Trial Group (FIRST Group) (1997) · Neurology · doi:10.1212/wnl.49.4.991 · Cited by 261
Rizzi, M., Caccia, S., Guiso, G., Richichi, C., Gorter, J. A., Aronica, E., Aliprandi, M., Bagnati, R., Fanelli, R., D'Incalci, M., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-14-05833.2002 · Cited by 243
Lazarowski, A., Czornyj, L., Lubienieki, F., Girardi, E., Vazquez, S., & D'Giano, C. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01302.x · Cited by 239
Potschka, H., Fedrowitz, M., & Löscher, W. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049858 · Cited by 234
Long‐term social outcomes for children with epilepsy
Camfield, C. S., & Camfield, P. R. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01390.x · Cited by 229
Potschka, H., Fedrowitz, M., & Löscher, W. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00423-8 · Cited by 226
The transport of antiepileptic drugs by P-glycoprotein
Zhang, C., Kwan, P., Zuo, Z., & Baum, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.003 · Cited by 225
Baltes, S., Gastens, A. M., Fedrowitz, M., Potschka, H., Kaever, V., & Löscher, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.038 · Cited by 223
Brandt, C., Bethmann, K., Gastens, A. M., & Löscher, W. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.014 · Cited by 221
Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy
Tan, N. C. K., Heron, S. E., Scheffer, I. E., Pelekanos, J. T., McMahon, J. M., Vears, D. F., Mulley, J. C., & Berkovic, S. F. (2004) · Neurology · doi:10.1212/01.wnl.0000137051.33486.c7 · Cited by 211
Van Vliet, E. A., Van Schaik, R., Edelbroek, P. M., Redeker, S., Aronica, E., Wadman, W. J., Marchi, N., Vezzani, A., & Gorter, J. A. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00496.x · Cited by 208
Potschka, H., Fedrowitz, M., & Löscher, W. (2001) · Neuroreport · doi:10.1097/00001756-200111160-00037 · Cited by 201
Aronica, E., Gorter, J. A., Ramkema, M., Redeker, S., Özbas‐Gerçeker, F., Van Vliet, E. A., Scheffer, G. L., Scheper, R. J., Van Der Valk, P., Baayen, J. C., et al. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.57703.x · Cited by 201
Siegmund, W., Ludwig, K., Giessmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kroemer, H. K., & Cascorbi, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127739 · Cited by 199
Expression of Multidrug Resistance-Associated Protein (MRP) in Brain Microvessel Endothelial Cells
Huai-Yun, H., Secrest, D. T., Mark, K. S., Carney, D., Brandquist, C., Elmquist, W. F., & Miller, D. W. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.8132 · Cited by 199
The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
van der Weide, J., Steijns, L. S. W., van Weelden, M. J. M., & de Haan, K. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00002 · Cited by 199
Aronica, E., Gorter, J. A., Jansen, G. H., van Veelen, C. W. M., van Rijen, P. C., Leenstra, S., Ramkema, M., Scheffer, G. L., Scheper, R. J., & Troost, D. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00992-2 · Cited by 197
Sills, G. J., Mohanraj, R., Butler, E., McCrindle, S., Collier, L., Wilson, E. A., & Brodie, M. J. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.46304.x · Cited by 194
Aronica, E., Gorter, J. A., Redeker, S., Van Vliet, E. A., Ramkema, M., Scheffer, G. L., Scheper, R. J., Van Der Valk, P., Leenstra, S., Baayen, J. C., et al. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.66604.x · Cited by 187
Use of Verapamil as a Potential P-Glycoprotein Inhibitor in a Patient with Refractory Epilepsy
Summers, M. A., Moore, J. L., & McAuley, J. W. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e068 · Cited by 184
Potschka, H., & Löscher, W. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.01901.x · Cited by 181
P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study
Feldmann, M., Asselin, M.-C., Liu, J., Wang, S., McMahon, A., Anton-Rodriguez, J., Walker, M., Symms, M., Brown, G., Hinz, R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70109-1 · Cited by 181
Refractory epilepsy: mechanisms and solutions
Kwan, P., & Brodie, M. J. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.397 · Cited by 179
Remission and relapse in a drug-resistant epilepsy population followed prospectively
Callaghan, B., Schlesinger, M., Rodemer, W., Pollard, J., Hesdorffer, D., Allen Hauser, W., & French, J. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02929.x · Cited by 176
Volk, H. A., & Löscher, W. (2005) · Brain · doi:10.1093/brain/awh437 · Cited by 170
Mechanisms of antiepileptic drug resistance
Sisodiya, S. M. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200304000-00013 · Cited by 164
Intrinsic Severity as a Determinant of Antiepileptic Drug Refractoriness
Rogawski, M. A., & Johnson, M. R. (2008) · Epilepsy Currents · doi:10.1111/j.1535-7511.2008.00272.x · Cited by 164
Refractory epilepsy: a progressive, intractable but preventable condition?
Kwan, P., & Brodie, M. J. (2002) · Seizure · doi:10.1053/seiz.2002.0593 · Cited by 161
Baltes, S., Fedrowitz, M., Tortós, C. L., Potschka, H., & Löscher, W. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102491 · Cited by 159
Beyenburg, S., Stavem, K., & Schmidt, D. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02299.x · Cited by 149
Löscher, W., Luna‐Tortós, C., Römermann, K., & Fedrowitz, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797440212 · Cited by 149
Calcium‐channel Blocker Verapamil Administration in Prolonged and Refractory Status Epilepticus
Iannetti, P., Spalice, A., & Parisi, P. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.59204.x · Cited by 147
Molecular Basis of the Polyspecificity of P-Glycoprotein (ABCB1)
Chufán, E. E., Sim, H., & Ambudkar, S. V. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2014.10.003 · Cited by 147
Carbamazepine is not a substrate for P‐glycoprotein
Owen, A., Pirmohamed, M., Tettey, J. N. A., Morgan, P., Chadwick, D. W., & Park, B. K. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01359.x · Cited by 146
Pharmacoresistance in Epilepsy: A Pilot PET Study with the P‐Glycoprotein SubstrateR‐[11C]verapamil
Langer, O., Bauer, M., Hammers, A., Karch, R., Pataraia, E., Koepp, M. J., Abrahim, A., Luurtsema, G., Brunner, M., Sunder‐Plaßmann, R., et al. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01116.x · Cited by 145
Neuropathology of the blood–brain barrier and pharmaco-resistance in human epilepsy
Liu, J. Y. W., Thom, M., Catarino, C. B., Martinian, L., Figarella‐Branger, D., Bartoloméi, F., Koepp, M. J., & Sisodiya, S. M. (2012) · Brain · doi:10.1093/brain/aws147 · Cited by 144
The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels
Kerb, R., Aynacioglu, A. S., Brockmöller, J., Schlagenhaufer, R., Bauer, S., Szekeres, T., Hamwi, A., Fritzer-Szekeres, M., Baumgärtner, C., Ongen, H. Z., et al. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500025 · Cited by 135
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition
Zibell, G., Unkrüer, B., Pekcec, A., Hartz, A. M. S., Bauer, B., Miller, D. S., & Potschka, H. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.009 · Cited by 134
Self-citationKwan, P., Poon, W. S., Ng, H., Kang, D. E., Wong, V. C. N., Ng, P. W., Lui, C. H. T., Sin, N. C., Wong, K. S., & Baum, L. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283117d67 · Cited by 128
Early predictors of outcome in newly diagnosed epilepsy
Mohanraj, R., & Brodie, M. J. (2013) · Seizure · doi:10.1016/j.seizure.2013.02.002 · Cited by 126
van Vliet, E. A., Redeker, S., Aronica, E., Edelbroek, P. M., & Gorter, J. A. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00250.x · Cited by 125
Refractory Epilepsy: A Clinically Oriented Review
Beleza, P. (2009) · European Neurology · doi:10.1159/000222775 · Cited by 119
A new hypothesis of drug refractory epilepsy: Neural network hypothesis
Fang, M., Xi, Z., Wu, Y. F., & Wang, X. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.02.039 · Cited by 118
van Vliet, E. A., van Schaik, R., Edelbroek, P. M., Voskuyl, R. A., Redeker, S., Aronica, E., Wadman, W. J., & Gorter, J. A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121178 · Cited by 117
Pharmacotherapy of Epilepsy: Newly Approved and Developmental Agents
Stephen, L. J., & Brodie, M. J. (2010) · CNS Drugs · doi:10.2165/11584860-000000000-00000 · Cited by 114
Evidence-based review on the natural history of the epilepsies
Schmidt, D., & Sillanpää, M. L. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283507e73 · Cited by 114
Road to refractory epilepsy: The G lasgow story
Brodie, M. J. (2013) · Epilepsia · doi:10.1111/epi.12175 · Cited by 112
García‐Bournissen, F., Moretti, M. E., Juurlink, D. N., Koren, G., Walker, M. J. K., & Finkelstein, Y. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01858.x · Cited by 112
Modulating P‐glycoprotein regulation: Future perspectives for pharmacoresistant epilepsies?
Potschka, H. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02585.x · Cited by 111
The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs
Rogawski, M. A. (2013) · Epilepsia · doi:10.1111/epi.12182 · Cited by 110
New Developments in Antiepileptic Drug Resistance: An Integrative View
Schmidt, D., & Löscher, W. (2009) · Epiliepsy currents/Epilepsy currents · doi:10.1111/j.1535-7511.2008.01289.x · Cited by 108
Bankstahl, J. P., & Löscher, W. (2008) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.07.007 · Cited by 106
Association between SCN1A polymorphism and carbamazepine‐resistant epilepsy
Abe, T., Seo, T., Ishitsu, T., Nakagawa, T., Hori, M., & Nakagawa, K. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03203.x · Cited by 104
Lakhan, R., Kumari, R., Misra, U. K., Kalita, J., Pradhan, S., & Mittal, B. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03437.x · Cited by 104
Ufer, M., Mosyagin, I., Muhle, H., Jacobsen, T., Haenisch, S., Häsler, R., Faltraco, F., Remmler, C., von Spiczak, S., Kroemer, H. K., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328329940b · Cited by 104
Novel approaches to epilepsy treatment
Sørensen, A. T., & Kokaia, M. (2012) · Epilepsia · doi:10.1111/epi.12000 · Cited by 103
A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose
Tate, S. K., Singh, R., Hung, C., Tai, J. J., Depondt, C., Cavalleri, G. L., Sisodiya, S. M., Goldstein, D. B., & Liou, H. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230114.41828.73 · Cited by 101
Camfield, C., CAMFIELD, P. R., Gordon, K., & Dooley, J. M. (1996) · Neurology · doi:10.1212/wnl.46.1.41 · Cited by 100
Targeting Prostaglandin E2 EP1 Receptors Prevents Seizure-Associated P-glycoprotein Up-Regulation
Pekcec, A., Unkrüer, B., Schlichtiger, J., Soerensen, J., Hartz, A. M. S., Bauer, B., van Vliet, E. A., Gorter, J. A., & Potschka, H. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152520 · Cited by 99
Self-citationRömermann, K., Helmer, R., & Löscher, W. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.01.015 · Cited by 95
P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice
Sills, G. J., Kwan, P., Butler, E., de Lange, E. C. M., van den Berg, D., & Brodie, M. J. (2002) · Epilepsy & Behavior · doi:10.1016/s1525-5050(02)00511-5 · Cited by 95
Sisodiya, S. M., Martinian, L., Scheffer, G. L., van der Valk, P., Scheper, R. J., Harding, B. N., & Thom, M. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00699.x · Cited by 89
Potschka, H., Baltes, S., & Löscher, W. (2004) · Epilepsy Research · doi:10.1016/j.eplepsyres.2003.12.007 · Cited by 88
Lazarowski, A., Ramos, A. J., Rivello, H. G., Brusco, A., & Girardi, E. (2004) · Cellular and Molecular Neurobiology · doi:10.1023/b:cemn.0000012726.43842.d2 · Cited by 88
Pirker, S., Schwarzer, C., Czech, T., Baumgartner, C., Pockberger, H., Maier, H., Hauer, B., Sieghart, W., Fürtinger, S., & Sperk, G. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.8.820 · Cited by 85
Advances in PET Imaging of P-Glycoprotein Function at the Blood-Brain Barrier
Syvänen, S., & Eriksson, J. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3001729 · Cited by 84
Haerian, B. S., Roslan, H., Raymond, A. A., Tan, C. T., Lim, K. S., Zulkifli, S. Z., Mohamed, E. H. M., Tan, H. J., & Mohamed, Z. (2010) · Seizure · doi:10.1016/j.seizure.2010.05.004 · Cited by 82
Major Vault Protein, a Marker of Drug Resistance, Is Upregulated in Refractory Epilepsy
Sisodiya, S. M., Martinian, L., Scheffer, G. L., van der Valk, P., Cross, J. H., Scheper, R. J., Harding, B. N., & Thom, M. (2003) · Epilepsia · doi:10.1046/j.1528-1157.2003.21803.x · Cited by 81
Kim, D. W., Kim, M., Lee, S. K., 강라미, & Lee, S.-Y. (2006) · Seizure · doi:10.1016/j.seizure.2006.02.015 · Cited by 79
Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine
Schmidt, D., & Haenel, F. (1984) · Neurology · doi:10.1212/wnl.34.9.1252 · Cited by 76
Surgical versus medical treatment for refractory epilepsy: Outcomes beyond seizure control
Perry, M. S., & DUCHOWNY, M. S. (2013) · Epilepsia · doi:10.1111/epi.12427 · Cited by 76
Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats
Potschka, H., Volk, H. A., & Löscher, W. (2004) · Neuroreport · doi:10.1097/01.wnr.0000134840.10390.a4 · Cited by 75
Refractory Epilepsy: One Size Does Not Fit All
French, J. A. (2006) · Epiliepsy currents/Epilepsy currents · doi:10.1111/j.1535-7511.2006.00137.x · Cited by 73
Potschka, H., & Löscher, W. (2001) · Neuroreport · doi:10.1097/00001756-200108080-00020 · Cited by 71
Mittal, B., Kumari, R., Lakhan, R., Garg, R., Kalita, J., & Misra, U. K. (2011) · Indian journal of human genetics · doi:10.4103/0971-6866.80357 · Cited by 69
Modern antiepileptic drugs: guidelines and beyond
Hitiris, N., & Brodie, M. J. (2006) · Current Opinion in Neurology · doi:10.1097/01.wco.0000218235.67840.82 · Cited by 68
The potential of pharmacogenetics in the treatment of epilepsy
Depondt, C. (2006) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2005.11.009 · Cited by 65
Fotoh, W. M. M. A. E., Naby, S. A. A. E., Habib, M. S. E., ALrefai, A. A., & Kasemy, Z. A. A. (2016) · Seizure · doi:10.1016/j.seizure.2016.07.005 · Cited by 65
Neligan, A., Bell, G. S., Sander, J. W. A. S., & Shorvon, S. D. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.06.004 · Cited by 62
Haerian, B. S., Lim, K. S., Tan, C. T., Raymond, A. A., & Mohamed, Z. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.212 · Cited by 61
Pardridge, W. M. (2003) · PubMed · Cited by 61
Zhang, C., Kwan, P., Zuo, Z., & Baum, L. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.04.008 · Cited by 60
Wen, T., Liu, Y.-C., Yang, H., Liu, H., Liu, X., Wang, G., & Xie, L. Y. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.02.016 · Cited by 59
van Vliet, E. A., Aronica, E., Redeker, S., Marchi, N., Rizzi, M., Vezzani, A., & Gorter, J. A. (2004) · Epilepsy Research · doi:10.1016/j.eplepsyres.2004.06.005 · Cited by 59
Lazarowski, A., Massaro, M., Schteinschnaider, Á., Intruvini, S., Sevlever, G. E., & Rabinowicz, A. L. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200402000-00010 · Cited by 57
Ak, H., Ay, B., Tanrıverdi, T., Sanuş, G. Z., İş, M., Sar, M., Öz, B., Özkara, Ç., Özyurt, E., & Uzan, M. (2007) · Seizure · doi:10.1016/j.seizure.2007.03.011 · Cited by 55
In vivo P-glycoprotein function before and after epilepsy surgery
Bauer, M., Karch, R., Zeitlinger, M. A., Liu, J. Y. W., Koepp, M. J., Asselin, M., Sisodiya, S. M., Hainfellner, J. A., Wadsak, W., Mitterhauser, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000858 · Cited by 54
Kwan, P., Wong, V. C. N., Ng, P. W., Lui, C. H. T., Sin, N. C., Poon, W. S., Ng, H., Wong, K. S., & Baum, L. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.32 · Cited by 52
Functional Expression of Drug Transporters in Glial Cells
Ashraf, T., Kao, A. C.-C., & Bendayan, R. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.06.010 · Cited by 52
Simon, C., Stieger, B., Kullak-Ublick, G. A., et al. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00761.x · Cited by 44
Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: A pilot study
Asadi‐Pooya, A. A., Razavizadegan, S. M. A., Abdi‐Ardekani, A., & Sperling, M. R. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.07.006 · Cited by 43
Mosyagin, I. G., Runge, U., Schroeder, H. W. S., Dazert, E., Vogelgesang, S., Siegmund, W., Warzok, R., & Cascorbi, I. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01661.x · Cited by 41
Ambroziak, K., Kuteykin‐Teplyakov, K. B., Luna‐Tortós, C., Alfalah, M., Fedrowitz, M., & Löscher, W. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.051 · Cited by 37
A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures
Borlot, F., Wither, R. G., Ali, A., Wu, N., Verocai, F., & Andrade, D. M. (2014) · Epilepsy Research · doi:10.1016/j.eplepsyres.2014.08.009 · Cited by 37
Grover, S., & Kukreti, R. (2013) · Epilepsia · doi:10.1111/epi.12132 · Cited by 36
Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication
Munagala, S., Sirasani, G., Kokkonda, P., Phadke, M. A., Krynetskaia, N. F., Lu, P., Sharom, F. J., Chaudhury, S., AbdulHameed, M. D. M., Tawa, G. J., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.12.022 · Cited by 36
Qian, L., Fang, S., Yan, Y., Zeng, S., Xu, Z., & Gong, Z. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.10.014 · Cited by 36
Etiology and management of refractory epilepsies
Sisodiya, S. M. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0521 · Cited by 35
Shin, J.-W., Chu, K., Shin, S. A., Jung, K., Lee, S., Lee, Y., Moon, J., Lee, D. Y., Lee, J. S., Lee, D. S., et al. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4566 · Cited by 34
Narayanan, J., Frech, R., Walters, S., Patel, V. A., Frigerio, R., & Maraganore, D. M. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.07.004 · Cited by 32
Salvamoser, J. D., Avemary, J., Luna‐Munguía, H., Pascher, B., Getzinger, T., Pieper, T., Kudernatsch, M., Kluger, G. J., & Potschka, H. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500841w · Cited by 28
Chen, Y., Wang, C., Xiao, X., Li, W., & Xu, G. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.183 · Cited by 23
Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil
Pirker, S., & Baumgartner, C. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03513.x · Cited by 22
Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery
Paul, F., Veauthier, C., Fritz, G., Lehmann, T., Aktaş, O., Zipp, F., & Meencke, H. (2007) · Seizure · doi:10.1016/j.seizure.2007.03.006 · Cited by 22
The role of common variation in drug transporter genes in refractory epilepsy
Soranzo, N., Goldstein, D. B., & Sisodiya, S. M. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.8.1305 · Cited by 21
Usefulness of Salivary Drug Monitoring for Detecting Efflux Transporter Overexpression
Fagiolino, P. L., Vázquez, M., Maldonado, C., Ruiz, M. E., Volonté, M. G., Orozco-Suárez, S. A., & Lazarowski, A. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990368 · Cited by 13
Dietary therapy is not the best option for refractory nonsurgical epilepsy
Vaccarezza, M. M., & Silva, W. H. (2015) · Epilepsia · doi:10.1111/epi.13074 · Cited by 12
Kukreti, R., Grover, S., & Gupta, M. (2011) · Indian journal of human genetics · doi:10.4103/0971-6866.80351 · Cited by 11
Cited by
Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 903
Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis
Sultana, B., Panzini, M.-A., Veilleux Carpentier, A., Comtois, J., Rioux, B., Gore, G., Bauer, P. R., Kwon, C.-S., Jetté, N., Josephson, C. B., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011839 · Cited by 435
Perucca, E., Perucca, P., White, H. S., & Wirrell, E. C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00151-5 · Cited by 305
Pharmacology of Medical Cannabis
Amin, M. R., & Ali, D. W. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-21737-2_8 · Cited by 278
The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
Fattorusso, A., Matricardi, S., Mencaroni, E., Dell'Isola, G. B., Di Cara, G., Striano, P., & Verrotti, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.674483 · Cited by 269
Metadata
- Authors
- Tang, F., Hartz, A. M. S., & Bauer, B.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2017-07-06
- Volume
- 8
- Pages
- 301-301
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2726666234
- Cited by
- 482
- References
- 147
- FWCI
- 26.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.